[144] Boston Scientific Corp. SEC Filing

Rhea-AI Filing Summary

Boston Scientific Corp. (BSX) filed a Form 144 indicating a proposed sale of 2,901 common shares through Morgan Stanley Smith Barney on or after 07/29/2025. The block is valued at approximately $310,378, based on the filing’s stated aggregate market value. The shares represent an immaterial 0.0002 % of BSX’s 1.48 billion shares outstanding.

The shares were acquired as restricted stock on 05/01/2025. No other sales by the filer have occurred in the past three months, and the notice affirms the absence of undisclosed material adverse information. A Form 144 is a routine regulatory notice and does not itself execute a sale; it merely provides advance disclosure of an intent to sell restricted or control securities under Rule 144.

Given the modest dollar amount and tiny percentage of float, the transaction is unlikely to be material to Boston Scientific’s capital structure or market liquidity. Investors typically monitor such filings for insider-sentiment cues, but under Rule 144 the filer must still comply with volume, manner-of-sale, and holding-period restrictions before selling.

Insights

Securities Analyst

TL;DR Minor insider sale (2,901 shares, $310k) signals little about BSX fundamentals; negligible market impact.

The Form 144 discloses an intended sale under Rule 144 of roughly $310 k in BSX stock—about two-ten-thousandths of shares outstanding. Such notices are routine for executives or affiliates converting restricted stock. Because the volume is far below Rule 144’s 1 % weekly limit, execution should not impair liquidity. No concomitant sales over the prior three months suggest this is a one-off diversification rather than a trend. Absent other negative disclosures, I view the filing as neutral to valuation and do not alter my investment thesis.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2901	310377.99	1479446345	07/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2025	Restricted Stock	Issuer			2901	05/01/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did Boston Scientific (BSX) file Form 144?

Form 144 notifies the SEC of an insider’s intent to sell restricted or control shares under Rule 144; BSX’s filer plans to sell 2,901 shares.

How many BSX shares are being sold and what is the value?

2,901 common shares valued at roughly $310,378 based on market price disclosed in the filing.

When is the planned sale date for the BSX shares?

The filer listed an approximate sale date of 07/29/2025 on the NYSE.

What percentage of Boston Scientific’s outstanding shares does the sale represent?

Only about 0.0002 % of the company’s 1.48 billion shares outstanding, an immaterial amount.

Does this Form 144 indicate undisclosed negative information at BSX?

No. The signer attests they possess no non-public adverse information; the notice is procedural and does not imply company performance issues.